Lineage Point Capital LP Invests $2.46 Million in Oaktree Acquisition Corp. III Life Sciences $OACC

Lineage Point Capital LP bought a new stake in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 232,642 shares of the company’s stock, valued at approximately $2,461,000. Lineage Point Capital LP owned approximately 1.04% of Oaktree Acquisition Corp. III Life Sciences at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Radcliffe Capital Management L.P. increased its position in shares of Oaktree Acquisition Corp. III Life Sciences by 175.5% during the third quarter. Radcliffe Capital Management L.P. now owns 225,662 shares of the company’s stock worth $2,372,000 after acquiring an additional 143,749 shares in the last quarter. Berkley W R Corp increased its position in shares of Oaktree Acquisition Corp. III Life Sciences by 125.2% during the third quarter. Berkley W R Corp now owns 223,645 shares of the company’s stock valued at $2,351,000 after acquiring an additional 124,315 shares during the last quarter. Empyrean Capital Partners LP grew its stake in Oaktree Acquisition Corp. III Life Sciences by 20.0% in the 4th quarter. Empyrean Capital Partners LP now owns 900,000 shares of the company’s stock valued at $9,522,000 after purchasing an additional 150,000 shares during the period. Readystate Asset Management LP purchased a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the 3rd quarter valued at $262,000. Finally, Whitebox Advisors LLC bought a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the 2nd quarter worth $2,612,000.

Oaktree Acquisition Corp. III Life Sciences Trading Up 0.2%

OACC opened at $10.67 on Friday. Oaktree Acquisition Corp. III Life Sciences has a twelve month low of $10.30 and a twelve month high of $10.74. The firm has a 50-day moving average price of $10.68 and a 200-day moving average price of $10.65.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last posted its earnings results on Thursday, March 26th. The company reported $0.08 earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Oaktree Acquisition Corp. III Life Sciences in a report on Thursday, April 2nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Oaktree Acquisition Corp. III Life Sciences currently has a consensus rating of “Sell”.

Oaktree Acquisition Corp. III Life Sciences Company Profile

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.